CareDx, Inc. (CDNA) Stake Held by TPG Group Holdings SBS Advisors Inc.
TPG Group Holdings SBS Advisors Inc. continued to hold its stake in shares of CareDx, Inc. (NASDAQ:CDNA) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 174,378 shares of the company’s stock at the end of the 2nd quarter. TPG Group Holdings SBS Advisors Inc. owned 0.81% of CareDx worth $194,000 at the end of the most recent quarter.
A number of other hedge funds have also recently modified their holdings of the business. Stonepine Capital Management LLC purchased a new position in shares of CareDx in the 2nd quarter worth about $212,000. Royce & Associates LP increased its position in shares of CareDx by 23.5% during the 1st quarter. Royce & Associates LP now owns 526,472 shares of the company’s stock valued at $737,000 after purchasing an additional 100,111 shares during the last quarter. Finally, Gagnon Securities LLC increased its position in shares of CareDx by 2.9% during the 2nd quarter. Gagnon Securities LLC now owns 2,084,292 shares of the company’s stock valued at $2,314,000 after purchasing an additional 57,954 shares during the last quarter. 29.15% of the stock is owned by hedge funds and other institutional investors.
CDNA has been the topic of a number of research reports. Zacks Investment Research raised CareDx from a “hold” rating to a “buy” rating and set a $1.25 price objective on the stock in a report on Friday, June 9th. Raymond James Financial, Inc. raised CareDx from a “market perform” rating to a “buy” rating and set a $6.50 target price for the company in a research note on Wednesday, September 27th. ValuEngine raised CareDx from a “strong sell” rating to a “sell” rating in a research note on Tuesday, September 26th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and set a $7.00 price target (up from $3.00) on shares of CareDx in a research report on Tuesday, September 26th.
COPYRIGHT VIOLATION WARNING: This piece was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/10/04/caredx-inc-cdna-stake-held-by-tpg-group-holdings-sbs-advisors-inc.html.
CareDx, Inc. (CDNA) traded down 2.21% during trading on Wednesday, hitting $4.43. 306,849 shares of the company traded hands. CareDx, Inc. has a 52 week low of $0.76 and a 52 week high of $4.75. The company’s 50 day moving average is $2.88 and its 200-day moving average is $1.61. The stock’s market capitalization is $99.86 million.
CareDx (NASDAQ:CDNA) last posted its earnings results on Thursday, August 10th. The company reported ($0.19) EPS for the quarter, hitting analysts’ consensus estimates of ($0.19). The company had revenue of $12.05 million for the quarter, compared to the consensus estimate of $11.87 million. CareDx had a negative return on equity of 85.68% and a negative net margin of 61.27%. Analysts predict that CareDx, Inc. will post ($0.82) earnings per share for the current year.
In other news, major shareholder Neil Gagnon bought 21,448 shares of the stock in a transaction dated Monday, August 28th. The stock was purchased at an average cost of $2.77 per share, for a total transaction of $59,410.96. Following the transaction, the insider now owns 903,731 shares of the company’s stock, valued at $2,503,334.87. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have bought a total of 65,874 shares of company stock worth $186,018 over the last ninety days. Insiders own 5.40% of the company’s stock.
CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
Receive News & Stock Ratings for CareDx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx Inc. and related stocks with our FREE daily email newsletter.